Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

Sponsor

AstraZeneca (Industry)

Overall Status

Completed

CT.gov ID

NCT01025479

Collaborator

(none)

829

Enrollment

Locations

3.9

Duration (Months)

46.1

Patients Per Site

11.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Condition or Disease	Intervention/Treatment	Phase
Prostate Cancer Osteoporosis

Study Design

Study Type:

Observational

Actual Enrollment :

829 participants

Observational Model:

Case-Only

Time Perspective:

Retrospective

Official Title:

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

Study Start Date :

Nov 1, 2009

Actual Primary Completion Date :

Mar 1, 2010

Actual Study Completion Date :

Mar 1, 2010

Outcome Measures

Primary Outcome Measures

To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage. []

Secondary Outcome Measures

To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study. []

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

pathologic confirmation of prostate cancer
patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria:

patients who are hard to be analysed by limitation of chart record according to investigators'discretion
patients who already have been registered in this study

Contacts and Locations

Locations

	Site	City	State	Country
1	Research Site	Cheongju-si	Chungcheongbuk-do	Korea, Republic of
2	Research Site	Chungju-si	Chungcheongbuk-do	Korea, Republic of
3	Research Site	Cheonan-si	Chungcheongnam-do	Korea, Republic of
4	Research Site	Gangneung-si	Gangwon-do	Korea, Republic of
5	Research Site	Goyang-si	Gyeonggi-do	Korea, Republic of
6	Research Site	Guri-si	Gyeonggi-do	Korea, Republic of
7	Research Site	Gumi-si	Gyeongsangbuk-do	Korea, Republic of
8	Research Site	Gyeongju-si	Gyeongsangbuk-do	Korea, Republic of
9	Research Site	Masan-si	Gyeongsangnam-do	Korea, Republic of
10	Research Site	Iksan-si	Jeollabuk-do	Korea, Republic of
11	Research Site	Daegu		Korea, Republic of
12	Research Site	Daejeon		Korea, Republic of
13	Research Site	Gwangju		Korea, Republic of
14	Research Site	Incheon		Korea, Republic of
15	Research Site	Jeju		Korea, Republic of
16	Research Site	Pusan		Korea, Republic of
17	Research Site	Seoul		Korea, Republic of
18	Research Site	Ulsan		Korea, Republic of